News

In a recently published paper in the Brain and Behavior journal entitled “Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington’s disease“, French CNRS researchers in collaboration with institutions from Gottingen in Germany, investigated the…

In a recent paper published in Nature Neuroscience journal entitled “Human mutant huntingtin disrupts vocal learning in transgenic songbirds“, Rockefeller University researchers reported that songbirds could be used as new tool to study Huntington’s disease (HD), providing a more complete understanding of the mechanisms underlying brain neurodegeneration.

In a recent study published in the journal PLOS Currents, a team of researchers from Cambridge in the United Kingdom developed a cheap motor task able to detect motor impairments in both premanifest and manifest Huntington’s disease (HD). According to the researchers the novel task might be a…

The New York Blood Center (NYBC) and the Howard and Abby Milstein Foundation recently announced plans to expand their partnership and joint efforts to further stem cell line technology and application in regenerative medicine. This expansion will also welcome Drs. Peter…

Cloud-based drug design and development company, Cloud Pharmaceuticals, Inc., recently announced it has signed with THERAMetrics holding AG to collaborate on breakthrough treatments for orphan central nervous system (CNS) diseases and other indications. This strategic collaboration has as its primary points of interest Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy…

A team of scientists at the University of Louisville are determined to find out if a promising treatment, VX15, an investigational monoclonal antibody, can delay the onset of or slow disease progression of Huntington’s Disease (HD). The study titled SIGNAL is a Phase II clinical trial that aims to determine the…

New research out of London has identified specific, highly connected brain regions, known as “rich club brain regions” that may be vulnerable in Huntington’s disease and possibly in other diseases in which there is progressive deterioration of brain cells (neurodegenerative diseases). The article, titled “Selective vulnerability of Rich…

In a new study entitled “Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral myelination” a team of scientists reports a new method for capturing and understanding the molecular mechanisms behind brain cellular interactions, a key event for a healthy and fully functional brain which may…

Bioinformatics, a field that enables powerful analysis of large amounts of data, is being applied to Huntington’s disease to find potential candidate molecules that play a role in pathogenesis. Researchers have conducted high throughput screens of genetic information, and this information is now being deciphered by different computer programs to…

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, recently announced it has agreed to amend its January 2012 collaboration and licensing agreement with Shire to accelerate the development of ZFP Therapeutics geared towards treated hemophilia A and B and Huntington’s disease. This agreement follows the companies’ mutual decision to refocus their research…